The lack of L-PG production and the repercussions of it in regards to M. Tuberculosis interactions with mononuclear phagocytes

Acta Microbiologica et Immunologica Hungarica

Volumn 60, Issue 2, 2013, Pages 127-144

  Fol, Marek ^a   Głlobińska, Anna ^a,b   Sta̧czek, Paweł ^a   Kowalewicz Kulbat, Magdalena ^a   Druszczyńska, Magdalena ^a   Madiraju, Murty ^c   Rudnicka, Wiesława ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

cathepsin G; HNP 1 3; lysinylation; MHC class II; tuberculosis

Indexed keywords

CATHEPSIN G; DEFENSIN 1; DEFENSIN 2; DEFENSIN 3; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; LYSINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; PHOSPHATIDYLGLYCEROL; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; LYSX GENE; MONOCYTE; MONONUCLEAR PHAGOCYTE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

EID: 84880194331     PISSN: 12178950     EISSN: 15882640     Source Type: Journal    
DOI: 10.1556/AMicr.60.2013.2.4     Document Type: Article

References (53)

1. Dye, C., Williams, B.G.: The population dynamics and control of tuberculosis. Science 328, 856-861 (2010).
2. Dye, C., Scheele, S., Dolin, P., Pathania, V., Raviglione, M.C.: Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282, 677-686 (1999).
3. Lin, P.L., Flynn, J.L.: Understanding latent tuberculosis: A moving target. J Immunol 185, 15-22 (2010).
4. Global Tuberculosis Control: Epidemiology, Strategy, Financing. WHO Report 2009. Geneva: WHO, 2009; http://www.who.int/tb/publications/global- report/en/http://www.who.int/tb/publications/global-report/en/(30.01.2011)
5. Flynn, J.: Immunology of tuberculosis and implications in vaccine development. Tuberculosis 84, 93-101 (2004).
6. Pieters, J.: Entry and survival of pathogenic mycobacteria in macrophages. Microbes Infect 3, 249-255 (2001).
7. Barreto, M.L., Pereira, S.M., Ferreira, A.A.: BCG vaccine: Efficacy and indications for vaccination and revaccination. J Pediatr 82, S45-S54 (2006).
8. Delogu, G., Fadda, G.: The quest for a new vaccine against tuberculosis. J Infect Dev Countries 3, 5-15 (2009).
9. McShane, H.: Vaccine strategies against tuberculosis. Swiss Med Wkly 139, 156-160 (2009).
10. Hett, E.C., Rubin, E.J.: Bacterial growth and cell division: A mycobacterial perspective. Microbiol Mol Biol Rev 1, 126-156 (2008).
11. Brennan, P.J., Nikaido, H.: The envelope of mycobacteria. Annu Rev Biochem 64, 29-63 (1995).
12. Goren, M.B.: Mycobacterial lipids: Selected topics. Bacteriol Rev 36, 33-64 (1972).
13. Peschel, A.: How do bacteria resist human antimicrobial peptides? Trends Microbiol 10, 179-186 (2002).
14. Kraus, D., Peschel, A.: Molecular mechanisms of bacterial resistance to antimicrobial peptides. Curr Top Microbiol Immunol 306, 231-250 (2006).
15. Peschel, A., Jack, R.W., Otto, M. Collins, L.V., Staubitz, P., Nicholson, G., Kalbachter, H., Nieuwenhuizen, W.F., Jung, G., Tarkowski, A., van Kessel, K.P., van Strijp, J.A.: Staphylococcus aureus resistance to human defensins and evasion of neutrohil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine. J Exp Med 193, 1067-1076 (2001).
16. Thedieck, K., Hain, T., Mohamed, W., Tindall, B.J., Nimtz, M., Chakraborty, T., Wehland, J., Jänsch, L.: The MprF protein is required for lysinylation of phospholipids in listerial membranes and confers resistance to cationic antimicrobial peptides (CAMPs) on Listeria monocytogenes. Mol Microbiol 62, 1325-1339 (2006).
17. Staubitz, P., Peschel, A.: MprF-mediated lysinylation of phospholipids in Bacillus subtilis-protection against bacteriocins in terrestrial habitats? Microbiology 148, 3331-3332 (2002).
18. Maloney, E., Stankowska, D., Zhang, J., Fol, M., Cheng, Q.J., Lun, S., Bishai, W.R., Rajagopalan, M., Chatterjee, D., Madiraju, M.V.: The two-domain LysX protein of Mycobacterium tuberculosis is required for production of lysinylated phosphatidylglycerol and resistance to cationic antimicrobial peptides. PLoS Pathogens 5, e1000534 (2009).
19. Maloney, E., Lun, S., Stankowska, D., Guo, H., Rajagopalan, M., Bishai, W.R., Madiraju, M.V.: Alterations in phospholipid catabolism in Mycobacterium tuberculosis lysX mutant. Front Microbiol 2, 19 doi: 10.3389/fmicb.2011.00019 (2011).
20. Khine, A.A., Del Sorbo, L., Vaschetto, R., Voglis S., Tullis, E., Slutsky, A.S., Downey, G.P., Zhang, H.: Human neutrophil peptides induce interleukin-8 production through the P2Y6 signaling pathway. Blood 107, 2936-2942 (2006).
21. Sharma, S., Verma, I., Khuller, G.K.: Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis. Antimicrob Agents Chemother 45, 639-640 (2001).
22. Ogata, K., Linzer, B.A., Zuberi, R.I., Ganz, T., Lehrer, R.I., Catanzaro, A.: Activity of defensins from human neutrophilic granulocytes against Mycobacterium avium-Mycobacterium intracellulare. Infect Immun 60, 4720-4725 (1992).
23. Chertov, O., Michiel, D.F., Xu, L., Wang, J.M., Tani, K., Murphy, W.J., Longo, D.L., Taub, D.D., Oppenheim, J.J.: Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem 271, 2935-2940 (1996).
24. Lillard, J.W. Jr, Boyaka, P.N., Chertov, O., Oppenheim, J.J., McGhee, J.R.: Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc Natl Acad Sci USA 96, 651-656 (1999).
25. Sparkes, R.S., Kronenberg, M., Heinzmann, C., Daher, K.A., Klisak, I., Ganz, T., Mohandas, T.: Assignment of defensin gene(s) to human chromosome 8p23. Genomics 5, 240-244 (1989).
26. Linzmeier, R., Michaelson, D., Liu, L., Ganz, T.: The structure of neutrophil defensin genes. FEBS Lett 321, 267-273 (1993).
27. Ganz, T., Lehrer, R.I.: Antimicrobial peptides of leukocytes. Curr Opin Hematol 4, 53-58 (1997).
28. Ulm, H., Wilmes, M., Shai, Y., Sahl, H.G.: Antimicrobial host defensins-specific antibiotic activities and innate defense modulation. Front Immunol 3, 249 (2012).
29. Kalita, A., Verma, I., Khuller, G.K.: Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. J Infect Dis 190, 1476-1480 (2004).
30. Sharma, S., Verma, I., Khuller, G.K.: Biochemical interaction of HNP-1 with Mycobacterium tuberculosis H37Ra. Arch Microbiol 171, 338-342 (1999).
31. Sharma, S., Verma, I., Khuller, G.K.: Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv: in vitro and ex vivo study. Eur Respir J 16, 112-117 (2000).
32. Soehnlein, O., Kai-Larsen, Y., Frithiof, R., Sorensen, O.E., Kenne, E., Scharffetter-Kochanek, K., Eriksson, E.E., Herwald, H., Agerberth, B., Lindbom, L.: Neutrophil primary granule proteins HBP and HNP1-3 boost bacterial phagocytosis by human and murine macrophages. J Clin Invest 118, 3491-3502 (2008).
33. Martineau, A.R., Newton, S.M., Wilkinson, K.A., Kampmann, B., Hall, B.M., Nawroly, N., Packe, G.E., Davidson, R.N., Griffiths, C.J., Wilkinson, R.J.: Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest 117, 1988-1994 (2007).
34. Wiedow, O., Meyer-Hoffert, U.: Neutrophil serine proteases: Potential key regulators of cell signalling during inflammation. J Intern Med 257, 319-328 (2005).
35. Heutinck K.M., ten Berge I.J.M., Hack C.E., Hamann J., Rowshani A.T.: Serine proteases of the human immune system in health and disease. Mol Immunol 47, 1943-1955 (2010).
36. Chertov, O., Yang, D., Howard, Z.M.O., Oppenheim, J.J.: Leukocyte granule proteins mobilize innate host defenses and adaptive immune responses. Immunol Rev 177, 68-78 (2000).
37. Rivera-Marrero, C.A., Stewart, J., Shafer, W.M., Roman, J.: The down-regulation of cathepsin G in THP-1 monocytes after infection with Mycobacterium tuberculosis is associated with increased intracellular survival of bacilli. Infect Immun 72, 5712-5721 (2004).
38. Aston, C., Rom, W.N., Talbot, A.T., Reibman, J.: Early inhibition of mycobacterial growth by human alveolar macrophages is not due to nitric oxide. Am J Respir Crit Care Med 157, 1943-1950 (1998).
39. Hari Sai Priya, V., Anuradha, B., Latha Gaddam, S., Hasnain, S.E., Murthy, K.J., Valluri, V.L.: In vitro levels of interleukin 10 (IL-10) and IL-12 in response to a recombinant 32-kilodalton antigen of Mycobacterium bovis BCG after treatment for tuberculosis. Clin Vaccine Immunol 16, 111-115 (2009).
40. Sendide, K., Deghmane, A.E., Pechkovsky, D., Av-Gay, Y., Talal, A., Hmama, Z.: Mycobacterium bovis BCG attenuates surface expression of mature class II molecules through IL-10 dependent inhibition of cathepsin S. J Immunol 175, 5324-5332 (2005).
41. Hmama, Z., Gabathuler, R., Jefferies, W.A., de Jong, G., Reiner, N.E.: Attenuation of HLA-DR expression by mononuclear phagocytes infected with Mycobacterium tuberculosis is related to intracellular sequestration of immature class II heterodimers. J Immunol 161, 4882-4893 (1998).
42. Noss, E.H., Harding, C.V., Boom, W.H.: Mycobacterium tuberculosis inhibitsMHCclass II antigen processing in murine bone marrow macrophages. Cell Immunol 201, 63-74 (2000).
43. Weinberg, J.B., Misukonis, M.A., Shami, P.J., Mason, S.N., Sauls, D.L., Dittman, W.A., Wood, E.R., Smith, G.K., McDonald, B., Bachus, K.E., Haney, A.F., Granger D.L.: Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): Analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 83, 1184-1195 (1995).
44. de Leeuw, E., Lu, W.: Human defensins: Turning defense into offense. Infect Disord Drug Targets 7, 67-70 (2007).
45. Nijnik, A., Hancock, R.: Host defence peptides: Antimicrobial and immunomodulatory activity and potential applications for tacking antibiotic-resistant infections. Emerg Health Threats J 2, e1 doi: 10.3134/ehtj.09.001 (2009).
46. Rehaume, L.M., Hancock, R.E.: Neutrophil-derived defensins as modulators of innate immune function. Crit Rev Immunol 28, 185-200 (2008).
47. Wilson, M., Seymour, R., Henderson, B.: Bacterial perturbation of cytokine networks. Infect Immun 66, 2401-2409 (1998).
48. Orme, I.M., Cooper, A.M.: Cytokine/chemokine cascades in immunity to tuberculosis. Immunol. Today 20, 307-312 (1999).
49. Winek, J., Demkow, U., Rowimska-Zakrzewska, E., Szolkowska, M., Filewska, M., Jagodzimski, J., Roszkowski-Sliz, K.: Comparison of Th1 and Th2 response in the blood of tuberculous patients and healthy contacts. Pneumonol Alergol Pol 77, 446-452 (2009).
50. Cooper, A.M., Roberts, A.D., Rhoades, A.R., Callahan, J.E., Getzy, D.M., Orme, I.M.: The role of IL-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 84, 423-432 (1995).
51. Flynn, J.L., Goldstein, M.M., Triebold, K.J., Sypek, J., Wolf, S., Bloom, B.R.: IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J Immunol 155, 2515-2524 (1995).
52. Moore, K.W., de Waal Malefyt, R., Coffman, R.L., O'Garra, A.: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19, 683-765 (2001).
53. D'Andrea, A., Aste-Amezaga, M., Valiante, N.M., Ma, X., Kubin, M., Trinchieri, G.: Interleukin 10 (IL-10) inhibits human lymphocyte interferon g production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 178, 1041-1048 (1993).